Subscribe
istock-504614468_brauns
brauns / iStockphoto.com
10 January 2019Americas

Gilead announces licence and collaboration deal with Yuhan

Gilead Sciences, a biopharmaceutical company based in the US, has entered into a licensing and collaboration agreement with South Korean healthcare company Yuhan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
South Korean global licensing spikes n 2018
22 January 2019   South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.
Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Americas
Gilead signs immuno-oncology deal with Tango
2 November 2018   California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Asia-Pacific
South Korean global licensing spikes n 2018
22 January 2019   South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.
Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Americas
Gilead signs immuno-oncology deal with Tango
2 November 2018   California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.

More on this story

Asia-Pacific
South Korean global licensing spikes n 2018
22 January 2019   South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.
Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Americas
Gilead signs immuno-oncology deal with Tango
2 November 2018   California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB